Exact Sciences Corporation (EXAS)

Last Price:  

Company Description

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $876.29M
Net Income (Most Recent Fiscal Year) $-83.99M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 12.94
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 5.40
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -27.58%
Net Margin (Trailing 12 Months) -10.04%
Return on Equity (Trailing 12 Months) -13.98%
Return on Assets (Trailing 12 Months) -7.70%
Current Ratio (Most Recent Fiscal Quarter) 6.09
Quick Ratio (Most Recent Fiscal Quarter) 5.81
Debt to Common Equity (Most Recent Fiscal Quarter) 0.64
Inventory Turnover (Trailing 12 Months) 4.39
Book Value per Share (Most Recent Fiscal Quarter) $17.62
Earnings per Share (Most Recent Fiscal Quarter) $-0.60
Earnings per Share (Most Recent Fiscal Year) $-1.49
Diluted Earnings per Share (Trailing 12 Months) $-0.78
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Common Shares Outstanding 149.92M
Free Float 147.22M
Market Capitalization $13.74B
Average Volume (Last 20 Days) 1.34M
Beta (Past 60 Months) 1.89
Percentage Held By Insiders (Latest Annual Proxy Report) 1.80%
Percentage Held By Institutions (Latest 13F Reports) 86.94%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%